Skip to content
naulon

Not checkedNot checked for notices yet.

Customized chemotherapy based on <it>epidermal growth factor receptor</it> mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial

Fujita Shiro, Katakami Nobuyuki, Masago Katsuhiro and 7 more

BMC Cancer · 2012

doi:10.1186/1471-2407-12-185 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

<p>Abstract</p> <p>Background</p> <p>Elderly patients are more vulnerable to toxicity from chemotherapy. Activating <it>epidermal growth factor receptor</it> (<it>EGFR</it>) mutations in non-small-cell lung cancer (NSCLC) are associated with enhanced response to EGFR tyrosine-kinase inhibitors. We studied patients with advanced NSCLC for whom treatment was customized based on <it>EGFR</it> mutation status.</p> <p>Methods</p> <p>We screened 57 chemotherapy-naïve patients with histologically or cytologically confirmed NSCLC, stage IIIB or IV, aged 70 years or older, and with an Eastern Cooperative Oncology Group performance status 0 or 1, for <it>EGFR</it> exon 19 codon 746–750 deletion and exon 21 L858R mutation. Twenty-two patients with <it>EGFR</it> mutations received gefitinib; 32 patients without mutations received vinorelbine or gemcitabine. The primary endpoint was the response rate.</p> <p>Results</p> <p>The response rate was 45.5% (95% confidence interval [CI]: 24.4%, 67.8%) in patients with <it>EGFR</it> mutations and 18.8% (95% CI: 7.2%, 36.4%) in patients without <it>EGFR</it> mutations. The median overall survival was 27.9 months (95%CI: 24.4 months, undeterminable months) in patients with <it>EGFR</it> mutations and 14.9 months (95%CI: 11.0 months, 22.4 months) in patients without <it>EGFR</it> mutations. In the gefitinib group, grade 3/4 hepatic dysfunction and dermatitis occurred in 23% and 5% of patients, respectively. In patients treated with vinorelbine or gemcitabine, the most common grade 3 or 4 adverse events were neutropenia (47%; four had febrile neutropenia), anemia (13%), and anorexia (9%). No treatment-related deaths occurred.</p> <p>Conclusions</p> <p>Treatment customization based on <it>EGFR</it> mutation status deserves consideration, particularly for elderly patients who often cannot receive second-line chemotherapy due to poor organ function or comorbidities.</p> <p>Trial registration</p> <p>This trial is registered at University hospital Medical Information Network-clinical trial registration (<url>http://www.umin.ac.jp/ctr/index/htm</url>) with the registration identification number C000000436.</p>

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.